Anti-Mouse NK1.1 – Purified in vivo PLATINUM™ Functional Grade

NK-1+ cells from mouse spleen and bone marrow

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

Clone PK136 recognizes mouse NK1.1.

NK1.1 is a type II membrane protein that is part of the C-type lectin superfamily. NK1.1 contains a transmembrane domain and a cytoplasmic domain that are characteristic of C-type lectins. The function of NK cells is to mediate cytotoxicity and to secrete cytokines after immune stimulation. NK1.1 has been correlated with lysis of tumor cells In vitro and rejection of bone marrow allografts In vivo. It is also involved in NK cell activation, IFN-γ production, and cytotoxic granule release. NK-1.1 is commonly used as a mouse NK cell marker.

NK-1.1 is encoded by the NKR-P1B/NKR-P1C gene and expressed on NK cells and NK-T cells in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129.

1. Ardolino, M. et al. (2018) J Clin Invest. 128(10):4654-4668. PubMed
2. Koo, GC. and Peppard, JR. (1986) Hybridoma 3:301